Syphilis testing outreach: USPSTF screening in pregnancy and for people at increased risk, Medicare STI screening, home tests and discreet texts

Syphilis testing sits where two kinds of outreach meet. For people who are pregnant, the federal recommendation is universal: screen early in pregnancy, whatever the risk. For everyone else, it is aimed at people at increased risk, and the groups that define risk are sensitive ones, built on sexual history, HIV status, drug use and time in jail or prison. That makes the service hard to market well. A page that treats everyone the same misses the pregnancy rule, and a reminder that names the reason a person was invited can expose them to a partner, a parent or an employer. This guide covers how a sexual health clinic, an OB-GYN or midwifery practice, a primary care practice, a community health center or an urgent care clinic can build syphilis testing pages, prenatal reminders and recall messages on the USPSTF recommendations and the Medicare rule as written, keep the recommendations and the coverage apart, and send people with symptoms to care instead of a screening slot.

Twelve related topics have their own guides and are not repeated here. Clinic marketing is covered in our guide to sexual health clinic marketing, and testing for related infections in our guides to HIV testing outreach, hepatitis B screening and vaccination outreach and hepatitis C testing and treatment outreach. Prenatal care settings are covered in our guides to OB-GYN practice marketing, doula, midwife and birth center marketing and maternal-fetal medicine practice marketing. Community settings are covered in our guides to community health center marketing, school-based health center marketing and mobile health clinic marketing, and tests sold straight to the public in our guides to direct-to-consumer lab testing marketing and pharmacist test and treat marketing.

What the federal sources say

The USPSTF makes the two screening recommendations, Medicare.gov says what Part B pays for, the CDC sets out clinical guidance and public pages, and FDA rules on tests and tracks drug supply. The points that shape a syphilis testing program’s marketing:

• The USPSTF final recommendation Syphilis Infection During Pregnancy: Screening (May 13, 2025) recommends early, universal screening for syphilis infection during pregnancy, and screening at the first available opportunity if a person was not screened early (grade A). It applies to all adolescents and adults who are pregnant, whether or not risk factors are present, and says screening should happen even if the first opportunity is at presentation for delivery.
• The same page says the USPSTF was not able to assess the effectiveness of screening more than once during pregnancy and is not making a recommendation for or against repeat screening. It reports that the CDC and other groups recommend rescreening at 28 weeks of gestation and at delivery for people at high risk, and that another group recommends rescreening for all pregnant people in the third trimester and at birth.
• The USPSTF final recommendation Syphilis Infection in Nonpregnant Adolescents and Adults: Screening (September 27, 2022) recommends screening in persons who are at increased risk for infection (grade A). It applies to adolescents and adults with no symptoms who have ever been sexually active, and not to pregnant people or to people with signs or symptoms. It names men who have sex with men, persons with HIV or other sexually transmitted infections, persons who use illicit drugs, and persons with a history of incarceration, sex work or military service, and asks clinicians to consider how widespread syphilis is in their community.
• On screening intervals, the 2022 page says evidence is limited for the general population, and that men who have sex with men or persons with HIV may benefit from screening at least once a year, or every 3 to 6 months if they continue to be at high risk.
• The Medicare.gov page Sexually transmitted infection (STI) screenings and counseling (no date shown, checked October 30, 2026) says Part B covers screenings for chlamydia, gonorrhea, syphilis and hepatitis B for people who are pregnant or at increased risk, once every 12 months or at certain times during pregnancy, when a health care provider orders the screening, and that the person pays nothing if the primary care doctor or provider accepts assignment. It also covers up to 2 behavioral counseling sessions a year in a primary care setting.
• The CDC Sexually Transmitted Infections Treatment Guidelines, 2021: Syphilis During Pregnancy (updated July 22, 2021, read through an archived copy) says all women should be screened at the first prenatal visit, that testing should also be done at 28 weeks and at delivery for those who live in communities with high rates of syphilis or were at risk during pregnancy, that anyone with a fetal death after 20 weeks should be tested, and that no mother or newborn should leave the hospital without the mother’s syphilis status documented at least once during pregnancy.
• The CDC page About Syphilis (updated January 30, 2025, read through an archived copy) describes the stages, says the first sore can be painless and go unnoticed, and lists signs of syphilis in the brain and nerves, the eye and the ear, which can happen at any stage. The CDC page About Congenital Syphilis (updated January 31, 2025, read through an archived copy) tells pregnant people to get a syphilis test the first time they see a health care provider during pregnancy.
• The MedlinePlus page Syphilis (last updated June 5, 2024) says syphilis can pass from mother to baby during pregnancy, that symptoms can go away and come back, and that sores make it easier to get or give HIV during sex.

Both USPSTF statements are recent, so we checked whether either is being redone. On October 30, 2026, neither page showed an update in progress, and the USPSTF Recommendations in Progress page did not list syphilis screening. It did list behavioral counseling for sexually transmitted infections, which the 2022 statement names as a related recommendation, so a page that mentions counseling should be checked again when that update is final.

The Task Force itself has changed. In Kennedy v. Braidwood Management, decided June 27, 2025, the Supreme Court held that Task Force members are inferior officers whose appointment by the Secretary of HHS is consistent with the Appointments Clause, with their work directed and supervised by the Secretary. On September 17, 2026, HHS announced eight new members who join the eight members already serving. Neither event changed the syphilis recommendations as of October 30, 2026, and we could not confirm developments after that date. A practice page should quote the recommendation in force on the day it is written and record that date in its review notes.

Two more federal facts changed after the older pages were written, and both matter for wording. First, on August 16, 2024, FDA granted marketing authorization through the De Novo pathway to the first at-home, over-the-counter test that detects syphilis antibodies in blood, and said results from that type of test alone are not sufficient to diagnose syphilis and should be followed by additional testing. FDA also created a device classification for tests of this type used by lay users, so later tests can reach the market through 510(k) clearance. Second, the FDA Drug Shortages database lists an injectable syphilis treatment as a current shortage, first posted on April 26, 2023 and still listed as current in an update dated October 21, 2026. We checked both on October 30, 2026 and name no product here.

Two points shape the marketing. First, the two USPSTF recommendations reach different people: every pregnant person, and nonpregnant people at increased risk. A page that blurs them either tells pregnant readers they only need a test if they are at risk, or tells the general public they need routine testing that the federal source does not recommend for people who are not at increased risk. Second, screening is for people with no symptoms. A person with a sore, a rash, eye or vision changes, hearing changes or a severe headache needs a visit, not a screening slot.

Testing pages and claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “syphilis test near me”, “syphilis testing near me free”, “rapid syphilis test near me” and “syphilis test kit near me” to a person who types “syphilis test near”, and “syphilis testing pregnancy”, “syphilis testing window”, “syphilis testing after treatment” and “syphilis testing interpretation” to a person who types “syphilis testing”. For “prenatal syphilis” they offer “prenatal syphilis screening” and “prenatal syphilis rescreen”, and for “syphilis test during pregnancy” they offer “syphilis test positive during pregnancy” and “false positive syphilis test during pregnancy”. For “free syphilis” they offer “free syphilis testing near me” and “free syphilis test at home”, and for “std testing clinic” they offer “std testing clinic walk in” and “std testing clinic same day results”. Billing terms such as “syphilis screening icd 10” appear too; those belong to the billing staff, not the patient page.

A page that holds up names the USPSTF and the date of each recommendation, says testing is recommended for every pregnant person early in pregnancy, describes the increased-risk groups in neutral words, explains that a positive screening result is followed by a second kind of test, explains Medicare’s conditions, and puts the symptoms line and the 911 line above the booking button. Questions about the window period, a result or a treatment plan are for a clinician to answer, not for a marketing page to settle.

Phrases that need rewriting:

• “Only high-risk moms need a syphilis test.” The USPSTF 2025 recommendation is for all pregnant people, whether or not risk factors are present. Say every pregnant patient is tested early in pregnancy, and that the clinician may test again later.
• “Everyone should get a syphilis test every year.” No federal source says that for the general public. The 2022 USPSTF statement recommends screening for people at increased risk, and names a yearly or more frequent interval only for men who have sex with men or people with HIV who continue to be at high risk. Quote the groups and the date.
• “Results in 15 minutes, know for sure today.” FDA said results from the home antibody test alone are not sufficient to diagnose syphilis, and the USPSTF describes two-step testing. Say a positive screening result needs a second test and a clinician’s review.
• “Fast cure, one shot and you’re done.” A promise about treatment, and an injectable syphilis treatment has been on the FDA shortage list since April 26, 2023. Say the clinician explains treatment and follow-up, and name no drug, dose or schedule.
• “Free STD testing for everyone.” Medicare.gov ties no-cost STI screening to pregnancy or increased risk, a provider’s order, and assignment. Say who qualifies, and that the practice checks coverage or funding before the visit.
• “100 percent confidential, your insurance will never know.” A promise the practice may not control: claims, explanation of benefits statements and public health reporting rules can apply. Describe what the practice does to keep visits private and point to the self-pay option.
• “Protect your baby from birth defects.” Fear wording that also turns a federal statement into a promise. Say the CDC tells pregnant people to get a syphilis test the first time they see a provider during pregnancy, and that the clinician explains results.
• “Gay men: you’re spreading it.” Shame and blame. Name the group in the USPSTF’s neutral words, or describe the service without naming a group at all.
• “Boost your immunity against STIs with our supplement.” A supplement claim with no source. Remove it, and follow the supplement section below.
• “We’ve tested thousands and caught hundreds of cases.” Numbers with no source. Remove them unless they are drawn from the practice’s own documented and reviewed records, with their date and limits stated.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. Quoting the federal sources as written, with each one named and dated, stays inside that standard; turning a federal statement into a promise to the reader does not.

Symptoms, urgent signs and 911 on every page and in every tool

A screening page is for people who feel well, so it has to send people with symptoms elsewhere. The CDC About Syphilis page lists sores, rashes, fever and swollen glands in the early stages, and says syphilis can reach the brain and nerves, the eye or the ear at any stage, with signs such as a severe headache, confusion, muscle weakness, eye pain or redness, vision changes, hearing loss, ringing in the ears or dizziness. Put plain lines above the booking button, on flyers and in reminders: this screening is for people with no symptoms; if you have a sore, a rash, eye pain, vision or hearing changes, or other symptoms that worry you, call [phone] and do not wait for a screening appointment; if you are pregnant and have concerns about your pregnancy, call your prenatal care provider; if you think you have a medical emergency, call 911.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools, and on cards handed out at a testing event. A tool should send any message that describes sudden vision loss, a severe headache with confusion, or another emergency to the 911 line and alert staff, pass questions about a result or a treatment to a clinician, pass pregnancy questions to the prenatal care team, and never tell a person whether they have syphilis or whether a result is a false positive. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Prenatal testing: early, and again when the clinician says so

The pregnancy recommendation is the simplest message in this field and the one with the widest reach: every pregnant person, early in pregnancy, whatever their risk. The searches for “prenatal syphilis screening” and “syphilis testing pregnancy” come from people who want to know why the test is in their prenatal labs, and a calm, sourced answer is good service. Prenatal syphilis testing rules are also set state by state, so the practice’s clinicians and counsel should confirm what applies before a page describes the schedule.

For prenatal pages and messages, keep these points:

• Say the test is part of prenatal care for every pregnant patient, name the USPSTF and its May 13, 2025 date, and say it does not mean anyone suspects an infection.
• Say the clinician may recommend testing again later in pregnancy or at delivery, and leave the schedule to the clinician. The USPSTF made no recommendation for or against repeat screening, while the CDC guidance recommends it for people at risk or in communities with high rates; a page that promises one schedule for everyone overstates either source.
• Reach people who start prenatal care late. The USPSTF says a person not screened early should be screened at the first available opportunity, even at delivery, so a page or ad for a first prenatal visit can say it is never too late to start care, without naming syphilis in the ad.
• Coordinate with the birthing hospital, the midwife or the birth center so the result is documented before discharge, as the CDC guidance describes. That is clinical work, but the patient instructions and portal messages around it may be written by the marketing or patient education team, and they should match the clinical plan.
• Do not tell a pregnant person that a positive screening result means their baby has or will have congenital syphilis. Say the clinician explains the result, the next test and the plan.
• Offer prenatal pages in the languages the practice’s patients speak. The CDC posts multilingual patient materials on prenatal syphilis screening; link to them rather than writing new medical text.

Our guides to OB-GYN practice marketing, doula, midwife and birth center marketing and maternal-fetal medicine practice marketing cover the wider rules for prenatal care pages.

Who to invite outside pregnancy, and in whose words

The 2022 recommendation is for people at increased risk, and the groups it names are ones a practice should never write on a postcard. The task is to reach people who would benefit without labeling anyone.

Keep these points:

• Describe the service, not the person. “Confidential syphilis and STI testing, walk in or book online” reaches the groups without naming them. Where a page lists who should test, quote the USPSTF list with its date and add that the clinician helps each person decide.
• Ask about sexual history, drug use and HIV status in the clinician’s intake, not on a public page, an ad form or a quiz.
• Offer a regular testing schedule only to people the clinician has placed on one. The USPSTF interval of at least once a year, or every 3 to 6 months for those at continued high risk, applies to men who have sex with men or people with HIV, as the clinician judges.
• Pair syphilis testing with the related tests the federal sources name, such as HIV and hepatitis B, without bundling people into tests they do not need. Our guides to HIV testing outreach and hepatitis B screening and vaccination outreach cover those programs, and our guide to chlamydia and gonorrhea screening outreach covers yearly screening and retest reminders.
• Teens can be in the increased-risk group, and the rules on a minor’s consent to STI testing and on what a parent can see are set state by state. Say on the page that the clinic explains its confidentiality rules for teens, and follow our guide to school-based health center marketing for school settings.
• People leaving jail or prison, people in substance use programs and veterans are named in the USPSTF list. Outreach through those programs needs the program’s agreement, its own privacy rules and wording that does not single anyone out; our guide to addiction treatment marketing covers substance use program rules.

Home tests, rapid tests and confirming results

The “syphilis test kit near me”, “rapid syphilis test near me” and “free syphilis test at home” searches show people looking for fast, private options. FDA’s August 16, 2024 announcement describes the first at-home, over-the-counter syphilis antibody test and says its results alone are not sufficient to diagnose syphilis. The USPSTF 2022 statement describes two testing sequences, each with a first test and a confirming test of a different kind.

For pages about home and rapid tests, keep these points:

• Describe a home or rapid test as a first step, in FDA’s words, and say a positive result is followed by laboratory testing through a health care provider.
• Say what the practice does with a positive home result: how to book, how fast the practice can see the person, and who explains the next test.
• Do not promise “same day results” for the full diagnosis. A practice can say when a first result is available and that confirming tests take longer, if that matches its lab’s process.
• Name no test brand, and do not say a test is “FDA-approved”. FDA described the home test as authorized through the De Novo pathway, and later tests of the same type may be cleared through 510(k).
• Answer “false positive syphilis test during pregnancy” searches with a referral to the clinician, not with odds. A page can say some first results are not confirmed by the second test, and that the clinician explains what the result means.
• A practice or lab that sells test kits straight to the public follows our guides to direct-to-consumer lab testing marketing and pharmacist test and treat marketing.

Treatment, shortages and what not to promise

Treatment belongs to the clinician, and the FDA Drug Shortages database has listed an injectable syphilis treatment as in shortage since April 26, 2023. A page or ad that promises a quick shot, names a drug or a dose, or offers treatment without a visit sets up claims the practice may not be able to keep. Say that a clinician explains treatment and follow-up testing, that partners may need testing too, and that the clinic works with the local health department where that applies.

Syphilis is a reportable condition, and positive results reach public health authorities under rules set by law. Under 45 CFR 164.512(b), a covered entity may disclose protected health information to a public health authority that is authorized by law to collect it for disease control. A page should not promise that no one outside the practice will ever see a result; it can say the practice shares information only as the law requires or allows, and that health department staff may contact the person about partner services. Partner notification messages are clinical and public health work, not marketing, and should never be sent from a marketing tool.

Medicare, private plans and free testing

Coverage pages draw the “syphilis testing near me free” and “free syphilis testing” searches. Answer them from the sources, with the date checked: Medicare Part B covers STI screening, including syphilis, for people who are pregnant or at increased risk, once every 12 months or at certain times during pregnancy, when a health care provider orders it, and the person pays nothing if the provider accepts assignment. Our guides to marketing to Medicare patients and marketing to Medicaid patients cover the wider program rules, which matter for prenatal care in particular.

Private plans follow 42 U.S.C. 300gg-13, which requires group health plans and health insurers to cover, without cost sharing, evidence-based items or services that have in effect a rating of A or B in the current USPSTF recommendations. Both syphilis recommendations are grade A, but the rule reaches the screening the recommendation describes, not every test or follow-up visit. Do not write “free under the ACA” or “covered by all insurance”; say the practice checks coverage before the visit. Cash prices for testing follow our guides to advertising cash prices and good faith estimates for self-pay patients, and a self-pay option should be described in plain words, without promising what an insurer will or will not see.

A free testing day, a gift card for coming in or a raffle at a testing event follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. Under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. Testing paid for by a public health grant should say so in the grant’s words, and a free test that leads to paid visits needs counsel’s review before it runs.

Supplements and immune products

Immune and sexual health products sold next to a testing program need the same care as any health claim. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement prevents, treats or clears an infection, and follow our guide to selling supplements in a medical practice.

Recall texts, letters and reminders

Testing programs reach patients through recall lists: pregnant patients with no syphilis result on file, patients a clinician has placed on a regular testing schedule, and patients due for a follow-up test. Under 45 CFR 164.501, a communication about the practice’s own treatment for an individual, such as a reminder to come in for recommended testing, can fall outside the definition of marketing, while a message that promotes a third party’s product or service generally needs a signed authorization under 45 CFR 164.508.

The words in the message matter as much as the rule. These lists are built from sexual history, HIV status and pregnancy, and a text, a postcard or a voicemail can be seen by a partner, a parent or an employer. Keep these points:

• Name no condition and no reason the patient qualifies. Write “[Practice name]: you are due for a visit. Call [phone] or book online.” and give details only after the patient signs in or calls.
• Do not write “syphilis”, “STI”, “STD”, “positive” or “because of your partner” on a postcard, an envelope, a caller ID name, a text or a voicemail.
• Use the contact method the patient chose for sensitive services, which may differ from the one on file for other visits, and honor a request to be reached only in the portal.
• Check records before the message goes out, so a pregnant patient who has been tested is not told they are overdue.
• Send messages in the language the patient chose, and honor opt-out requests in every channel.
• Do not send recall lists, test orders, pregnancy status or HIV status to an ad platform to build an audience.

Our guides to text message appointment reminders and the patient recall system cover consent, timing and opt-outs.

Partners, sponsors and referral payments

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a syphilis testing program, keep these points:

• Do not pay a bar, an event host, an outreach worker, a shelter or a community group per person tested or referred, and do not accept payment from a lab or a pharmacy for sending patients there, without counsel’s review.
• Do not accept free test kits, staff, event funding or marketing help from a test maker, a lab or a drug maker tied to the tests or treatment the program orders, without counsel’s review; our guide to Open Payments and the Sunshine Act covers industry payments.
• If a prenatal practice, a sexual health clinic and a health department share patients, put the terms in writing, let the patient choose where to go, and follow our guide to patient and physician referrals.

Privacy, pixels and ads

A visit to a syphilis testing page, a booking for an STI visit or a home test order can say something sensitive about the person. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place, language settings and search terms, and should not be built from a list of patients tested, a list of pregnant patients or any audience defined by sexual orientation. Our guide to sexual health clinic marketing covers ad wording rules for sexual health services.

Tone and patient stories

People search for syphilis testing with worry, and some with shame. Lead with what the visit is: a blood test, private, for people who want to know, and part of routine prenatal care. Offer walk-in or evening times if the practice has them, say who will see the result, and keep fear and blame out of it: no images of sores, no newborn images tied to infection, no wording that blames a person or a group. Respect a person who declines, and say a clinician will answer questions. Offer the page in the languages the practice’s patients speak; our guide to Spanish language medical marketing covers translation.

A story from a patient who was tested can carry the message, but this is a field where a story can expose the person telling it. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. Use a story only if the patient chose to share it in writing, get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, never name a diagnosis or a result without that consent, say if the person received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two syphilis testing messages

Illustration: a flyer reads “Free STD testing for everyone! Results in 15 minutes, know for sure today. Only high-risk moms need a syphilis test. One shot and you’re cured. Your insurance will never know. Protect your baby from birth defects. We’ve caught hundreds of cases!” It misstates the pregnancy recommendation, promises a diagnosis from a first test, promises treatment, promises free care without the conditions, promises privacy the practice may not control, uses fear and uses a number with no source.

Illustration: a second flyer for the same practice reads “Pregnant? The U.S. Preventive Services Task Force (May 13, 2025) recommends syphilis screening for every pregnant person, early in pregnancy. Your prenatal team includes it in your first labs and will tell you if you need another test later. Not pregnant? The Task Force (September 27, 2022) recommends screening for people at increased risk; talk with our clinicians, privately, about whether testing is right for you. Medicare Part B covers STI screening for people who qualify, with a provider’s order; we check your coverage first, and we offer a self-pay option. This screening is for people with no symptoms. If you have a sore, a rash, eye pain or vision or hearing changes, call [phone]. If you think you have a medical emergency, call 911. [Practice name], [days and hours].” It quotes the sources and dates, separates the two groups, states the coverage conditions and puts the symptoms and 911 lines on the flyer.

Checklist before a syphilis testing campaign goes live

• Testing copy built on the USPSTF 2025 pregnancy recommendation and the 2022 increased-risk recommendation, each named and dated; the USPSTF site checked for an update on the day the page is written, with the date recorded in the page’s review notes.
• Prenatal pages say testing is for every pregnant patient, early, and leave repeat testing to the clinician; state prenatal testing rules confirmed by counsel.
• Increased-risk pages describe the service, not the person; risk questions asked in the clinician’s intake, not on a public form.
• Home and rapid tests described as a first step, in FDA’s words, with confirming tests and a clinician’s review; no test brand, no “FDA-approved”, no “know for sure today”.
• No treatment promises, no drug or dose names, and no “one shot” wording; the shortage status checked in the FDA database before any treatment wording runs.
• Medicare coverage described as Medicare.gov states it; private plan coverage checked per patient; no “free for everyone” and no promise about what an insurer will see.
• The symptoms line and the 911 line on pages, flyers, event cards, voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools, reviewed by the practice’s clinicians.
• Recall texts, postcards, caller ID names and voicemails name no condition, no test and no reason; the patient’s chosen contact method used; opt-outs honored.
• No per-person payments to hosts, outreach workers, labs or pharmacies, and no industry funding tied to tests or treatment, without counsel’s review; free testing and incentives reviewed under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5).
• No supplement claims; form answers, bookings and patient lists stay out of pixels and ad audiences; stories have signed authorizations and say results differ.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including sexual health clinics, OB-GYN and midwifery practices, primary care practices, community health centers and urgent care clinics. For a syphilis testing program, that means a site that builds its testing pages on the USPSTF recommendations as written and dated, separates the pregnancy recommendation from the increased-risk one and both from coverage, puts the symptoms and 911 lines above the booking button, and answers “prenatal syphilis screening” and “syphilis test near me” searches honestly, plus appointment request pages that book the visit and keep sexual history, pregnancy and test answers off the web and away from tracking tools. Our front desk tools send emergency messages to the 911 line, hand result, treatment and pregnancy questions to a clinician, and do not tell anyone whether they have an infection. We do not decide who should be tested; your clinicians and patients do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• USPSTF: Syphilis Infection During Pregnancy: Screening (final recommendation, May 13, 2025)
• USPSTF: Syphilis Infection in Nonpregnant Adolescents and Adults: Screening (final recommendation, September 27, 2022)
• USPSTF: Recommendations in Progress (checked October 30, 2026)
• HHS: Secretary Kennedy Announces New Appointments to U.S. Preventive Services Task Force (September 17, 2026)
• Kennedy v. Braidwood Management, Inc. (U.S. Supreme Court, decided June 27, 2025)
• Medicare.gov: Sexually transmitted infection (STI) screenings and counseling (checked October 30, 2026)
• CDC: Sexually Transmitted Infections Treatment Guidelines, 2021: Syphilis During Pregnancy (updated July 22, 2021)
• CDC: About Syphilis (updated January 30, 2025)
• CDC: About Congenital Syphilis (updated January 31, 2025)
• CDC: Syphilis Prenatal Screening (Protect Your Baby) (updated April 16, 2025)
• MedlinePlus: Syphilis (last updated June 5, 2024)
• FDA: FDA Marketing Authorization Enables Increased Access to First Step of Syphilis Diagnosis (August 16, 2024)
• FDA: Drug Shortages database (checked October 30, 2026)
• 42 U.S.C. 300gg-13: Coverage of preventive health services
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 45 CFR 164.512: Uses and disclosures for which an authorization or opportunity to agree or object is not required
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing